Pembrolizumab (Keytruda®) 1L NSCLC with chemotherapy

Assessment Status Assessment process complete
Drug Pembrolizumab
Brand Keytruda®
Indication In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.
Assessment Process
Rapid review commissioned 14/08/2018
Rapid review completed 29/08/2018
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 14/09/2018
Pre-submission consultation with Applicant 22/10/2018
Full submission received from Applicant 20/12/2018
Preliminary review sent to Applicant 14/06/2019
NCPE assessment re-commenced 10/07/2019
Factual accuracy sent to Applicant 31/07/2019
NCPE assessment re-commenced 09/08/2019
NCPE assessment completed 15/08/2019
NCPE assessment outcome The NCPE recommends that pembrolizumab (Keytruda®), prescribed in combination with platinum chemotherapy plus pemetrexed for the first line treatment of non-squamous NSCLC, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medial Goods) Act 2013.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations – February 2021.